Lianchuan Bio Secures Over RMB 115 Million in Series B Funding to Accelerate Domestication of Key Clinical Gene Detection Technologies

Recently, Hangzhou Lianchuan Biological Information Co., Ltd. announced the completion of its Series B financing round, totaling RMB 115 million. The round was led by Hangzhou Heda Biopharmaceutical Venture Capital, with participation from Beijing Junchuan Capital, Hangzhou Taimeng Investment, and existing shareholders including Huarui Investment, Zheshang Venture Capital, and Rushan Capital. The funds raised will be utilized for the research and development of Lianchuan Biology’s proprietary gene capture and gene synthesis platforms, as well as for technological translation and market development in the field of clinical genetic testing.

Hangzhou Lianchuan Biological Information Co., Ltd. was founded in 2006 as a high-tech biotechnology company specializing in personalized genetic testing solutions and products for research institutions and enterprises in the precision medicine sector.

In recent years, Hangzhou Lianchuan Biological Information Co., Ltd. has been dedicated to the efficient clinical application of genetic testing technologies, addressing the critical challenge of controlling costs while ensuring accuracy and rapid turnaround times. After years of technical breakthroughs, Lianchuan’s scientific team has developed VariantPro™, a one-step targeted gene capture technology. By incorporating molecular barcodes, this technology significantly enhances detection sensitivity. Furthermore, by simplifying complex, multi-step capture processes into a single step, it reduces time costs and minimizes human operational errors, thereby ensuring result accuracy. Leveraging its proprietary gene synthesis platform, Lianchuan can synthesize capture probes on a large scale with high fidelity, overcoming the high barriers and substantial costs associated with producing key raw materials for genetic testing kits. This lays the foundation for achieving fully integrated, rapid genetic testing. Moving forward, Lianchuan will accelerate the localization and domestic production of key links in the gene sequencing industry chain, breaking China’s heavy reliance on imports and the resulting high costs in the genetic testing sector.

Genetic testing has become a crucial component of the national "Precision Medicine" strategic plan. However, apart from the non-invasive prenatal testing (NIPT) market, which is approaching maturity, downstream clinical application scenarios—including screening for genetic disorders, early cancer detection and personalized medication, companion diagnostics, and pharmacogenomics—remain in the early stages of rapid growth. With continuous advancements in genetic testing technologies and declining costs, the clinical application of genetic testing is expected to exceed expectations in the near future.

For the gene sequencing industry, 2019 was a winter of capital. Compared with the total financing amount of about 1 billion yuan each year in 2017 and 2018, there was a precipitous decline in 2019. The outbreak of the COVID-19 pandemic and other global public health emergencies in early 2020 further cooled the investment climate across the entire gene sequencing sector. In the wake of the pandemic’s ripple effects, national investment in public health has continued to increase. Genetic testing is bound to gain broader public understanding and acceptance, opening up significant potential for market expansion.

Regarding this financing round, Dr. Lang Qiulei, Chairman of Lianchuan Biology, stated: “The Chinese genetic testing market is developing rapidly, with application scenarios expanding quickly. This presents both uncharted opportunities and significant challenges for us. For over a decade, Lianchuan Biology has been dedicated to the research and development of high-efficiency, low-cost gene capture technologies, striving to apply them in clinical diagnostics, such as targeted tumor diagnosis, pathogen detection, personalized medication, and early cancer screening. In the future, Lianchuan Biology will continue to focus on efficiently addressing the technological translation and market development of genetic testing in clinical applications, contributing to the localization of key technologies within the genetic testing industry chain.”

Hangzhou Lianchuan Biological Information Co., Ltd. was established in 2006 by overseas-returning high-level experts possessing core technologies. It is one of the few national high-tech enterprises worldwide to master core gene capture technologies. In 2016, it founded its wholly-owned subsidiary, Hangzhou Lianchuan Gene Diagnosis Technology Co., Ltd., and in 2018, officially established its second subsidiary, Hangzhou Liankang Medical Laboratory.

In the field of genetic technology, Lianchuan possesses the industry-leading µParaflo^®With its synthetic biology platform, single-cell capture and sequencing platform, high-throughput sequencing platform, and mass spectrometry analysis platform, the company provides cross-omics integrated analysis services spanning genomics, transcriptomics, epigenomics, proteomics, and metabolomics, committed to delivering world-class gene technology services and products to research institutions. In the field of precision medicine, Lianchuan scientists have developed VariantPro™, the world’s first one-step targeted gene capture technology, and successfully launched multiple liquid biopsy test kits for cancer detection. Leveraging its proprietary VariantBaits™ solution-phase hybridization capture system, the company is dedicated to providing enterprise clients with more precise and rapid customized products and services. Furthermore, Lianchuan has established a strategic partnership with Biolidics, a Singapore-based medical technology company, to jointly develop novel and efficient cancer diagnostic solutions based on circulating tumor cell (CTC) detection.

After fourteen years of rapid development, Lianchuan has become a renowned enterprise in the fields of genomics and precision medicine. Upholding its vision of “leading independent innovation in gene technology and building a well-known brand in precision medicine,” the company remains dedicated to providing personalized genetic testing solutions and products to research institutions and enterprises in the precision medicine sector.